Scarica l'app Stockscreener
36.46
1.67%
0.60
Dopo l'orario di chiusura:
35.90
-0.56
-1.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Henry Fernandez Steps Down from Royalty Pharma’s Board of Directors - citybiz
Royalty Pharma lead independent director Fernandez steps down By Investing.com - Investing.com Nigeria
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - The Manila Times
Henry Fernandez steps down from Royalty Pharma board - StreetInsider
Royalty Pharma's Lead Independent Director Exits Following Successful Post-IPO Growth Period - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Raised to Buy at Wall Street Zen - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 55,400 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Ex-Dividend Reminder: Eli Lilly, Teleflex and Royalty Pharma - Nasdaq
Forsta AP Fonden Sells 169,100 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Swiss National Bank Trims Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc a potential multi baggerGlobal Markets & Fast Gaining Stock Reports - kangso.co.kr
Vanguard Group Inc. Sells 676,561 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - Insider Monkey
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments - Yahoo Finance
Cary Street Partners Financial LLC Makes New Investment in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Director Norden Gregory Sells 33,500 Shares at $36.23 on 8/11/2025 - AInvest
CenterBook Partners LP Sells 41,728 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model - MSN
Royalty Pharma PLC (NASDAQ:RPRX) Shares Bought by Koss Olinger Consulting LLC - MarketBeat
Did Rising Costs and Lower Margins Just Shift Royalty Pharma's (RPRX) Investment Narrative? - simplywall.st
Royalty Pharma: Keep Delivering, Buy Confirmed (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma’s Earnings Call Highlights Strong Growth and Strategic Moves - The Globe and Mail
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's Why - MarketBeat
More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream - insights.citeline.com
UBS Adjusts Price Target on Royalty Pharma to $37 From $36, Maintains Neutral Rating - MarketScreener
Royalty Pharma plc (NASDAQ:RPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
PTC Therapeutics Earnings Preview: Analysts Expect $-1.07 EPS, Historical Performance and Stock Performance - AInvest
Royalty Pharma Reports Strong Q2 2025 Results - TipRanks
Royalty Pharma (RPRX) Q2 Receipts Up 20% - Mitrade
Royalty Pharma Plc Q2 Income Retreats - Nasdaq
Royalty Pharma Raises 2025 Portfolio Receipts Guidance to $3.05B-$3.15B, Achieving 20% Growth in Top Line - AInvest
Royalty Management Holding Corporation shares rise 5.65% intraday after Royalty Pharma plc reports Q2 2025 results. - AInvest
Royalty Pharma stock price target raised to $48 from $42 at BofA Securities - Investing.com UK
Royalty Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Royalty Pharma (RPRX) PT Raised to $48 at BofA Securities - StreetInsider
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates - sharewise.com
Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth By Investing.com - Investing.com Australia
Royalty Pharma earnings missed by $0.99, revenue fell short of estimates - Investing.com Nigeria
Royalty Pharma plc SEC 10-Q Report - TradingView
Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth - Investing.com
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings - Yahoo Finance
Transcript : Royalty Pharma plc, Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Royalty Pharma reports second quarter 2025 results - MarketScreener
Royalty Pharma Q2 2025 slides: Double-digit growth and raised guidance By Investing.com - Investing.com South Africa
Royalty Pharma Q2 2025 slides: Double-digit growth and raised guidance - Investing.com India
Royalty Pharma Q2 Net Income Falls, Revenue Rises - MarketScreener
Royalty Pharma Reports Second Quarter 2025 Results - TradingView
Earnings Flash (RPRX) Royalty Pharma plc Reports Q2 Revenue $579.0M - MarketScreener
53,119 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by XTX Topco Ltd - MarketBeat
Mackenzie Financial Corp Purchases 205,356 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
HB Wealth Management LLC Invests $392,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma stock hits 52-week high at 37.91 USD - Investing.com
Royalty Pharma stock hits 52-week high at 37.91 USD By Investing.com - Investing.com Canada
5.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):